EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials

John W Eikelboom, Jeffrey I Weitz

Journal of Thrombosis and Haemostasis · 2023-11 · 21 (11) · 3067-3071

DOI: 10.1016/j.jtha.2023.06.036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-11. Verfasst von John W Eikelboom und 1 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada;…. Hauptthemen laut MEDLINE: Rheumatic Heart Disease, Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although guidelines give preference to direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF), DOACs are not recommended in those with rheumatic heart disease or mechanical heart valves. The results of the INVICTUS trial (Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies), which compared rivaroxaban with a VKA in patients with rheumatic heart disease-associated AF, and the PROACT Xa trial (A Trial to Determine if Participants with an On-X Aortic Valve Can be Maintained Safely on Apixaban), which compared apixaban with warfarin in patients with an On-X valve in the aortic position, support the use of VKAs for these indications. In this paper, we review the results of these trials, provide perspective on why VKAs were superior to DOACs, and discuss future directions for anticoagulation in these disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rheumatic Heart DiseaseAtrial FibrillationStrokeHumansWarfarinRivaroxabanAnticoagulantsPyridonesVitamin KAdministration, OralFibrinolytic AgentsDabigatranPyrazoles

Stichwörter der Autor:innen

DOACINVICTUSPROACT Xamechanical heart valverheumatic heart diseasewarfarin

Substanzen

WarfarinRivaroxabanAnticoagulantsPyridonesVitamin KFibrinolytic AgentsDabigatranapixabanPyrazoles

Autor:innen und Institutionen

  • Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada.
  • Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Biochemistry and Biomedical Sciences, McMaster Universi…

Zitieren

APA

Eikelboom, J. W., & Weitz, J. I. (2023). Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. Journal of Thrombosis and Haemostasis, 21(11), 3067-3071. https://doi.org/10.1016/j.jtha.2023.06.036

Vancouver

Eikelboom JW, Weitz JI. Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. Journal of Thrombosis and Haemostasis. 2023;21(11):3067-3071. doi:10.1016/j.jtha.2023.06.036

BibTeX
@article{Eikelboom2023,
  author = {Eikelboom, John W and Weitz, Jeffrey I},
  title = {Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {11},
  pages = {3067--3071},
  doi = {10.1016/j.jtha.2023.06.036}
}
Kostenlos starten →